These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25164691)

  • 1. Assessment of Progression-Free-Survival in Glioblastomas by Intratreatment Dynamic Contrast-Enhanced MRI.
    Bisdas S; Smrdel U; Bajrovic FF; Surlan-Popovic K
    Clin Neuroradiol; 2016 Mar; 26(1):39-45. PubMed ID: 25164691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
    Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
    AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients.
    Ulyte A; Katsaros VK; Liouta E; Stranjalis G; Boskos C; Papanikolaou N; Usinskiene J; Bisdas S
    Neuroradiology; 2016 Dec; 58(12):1197-1208. PubMed ID: 27796446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
    Ly KI; Vakulenko-Lagun B; Emblem KE; Ou Y; Da X; Betensky RA; Kalpathy-Cramer J; Duda DG; Jain RK; Chi AS; Plotkin SR; Batchelor TT; Sorensen G; Rosen BR; Gerstner ER
    Sci Rep; 2018 Nov; 8(1):17062. PubMed ID: 30459364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
    Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography.
    Huang YS; Chen JL; Chen JY; Lee YF; Huang JY; Kuo SH; Yen RF; Chang YC
    Strahlenther Onkol; 2019 Aug; 195(8):707-718. PubMed ID: 30610356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy.
    Xu L; Ge X; Sun N; Liu X
    Acta Radiol; 2020 Oct; 61(10):1316-1325. PubMed ID: 32053003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
    Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
    AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.
    Kim KA; Park MS; Ji HJ; Park JY; Han KH; Kim MJ; Kim KW
    J Magn Reson Imaging; 2014 Feb; 39(2):286-92. PubMed ID: 24302545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.
    Choi YS; Kim DW; Lee SK; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Ahn SS
    AJNR Am J Neuroradiol; 2015 Dec; 36(12):2235-41. PubMed ID: 26338911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of dynamic contrast-enhanced magnetic resonance imaging for differentiating glioblastoma, primary central nervous system lymphoma and brain metastatic tumor.
    Lu S; Gao Q; Yu J; Li Y; Cao P; Shi H; Hong X
    Eur J Radiol; 2016 Oct; 85(10):1722-1727. PubMed ID: 27666608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment diffusion-weighted and dynamic contrast-enhanced MRI for prediction of local treatment response in squamous cell carcinomas of the head and neck.
    Chawla S; Kim S; Dougherty L; Wang S; Loevner LA; Quon H; Poptani H
    AJR Am J Roentgenol; 2013 Jan; 200(1):35-43. PubMed ID: 23255739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI.
    Guo P; Liu Z; Yan F; Wang J; Wei L; Lv H; Wang Z; Xian J
    Acta Radiol; 2016 Dec; 57(12):1490-1496. PubMed ID: 27012277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions.
    Heye T; Davenport MS; Horvath JJ; Feuerlein S; Breault SR; Bashir MR; Merkle EM; Boll DT
    Radiology; 2013 Mar; 266(3):801-11. PubMed ID: 23220897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.